Vladimir Khavinson's Research Program • 40+ Years

Khavinson Bioregulators: The Complete Guide

Last updated: March 2026

Ultra-short peptides that skip surface receptors and talk directly to DNA. Here's the complete breakdown of all 11 bioregulators, how to stack them, and why they work differently from everything else.

0
Years of Research
by Khavinson's Team
0
Patients Treated in
Russian Program
0
Bioregulators
Cataloged Here

Not Like Other Peptides

Most peptides bind surface receptors. Khavinson bioregulators do something fundamentally different — and that's why they've attracted 40+ years of research.

🔗
Traditional Peptides
  • Bind cell surface receptors (GPCR, tyrosine kinase, etc.)
  • Trigger signaling cascade inside cell
  • Signal degrades — effect fades when peptide clears
  • Downstream effects only — can't directly change gene expression
  • Examples: BPC-157, TB-500, GLP-1, GH secretagogues
🧬
Khavinson Bioregulators
  • Ultra-short (2–4 amino acids) — pass through cell membrane
  • Enter cell nucleus directly
  • Interact with DNA promoter regions and histones
  • Regulate gene expression at the source
  • Effect can persist after peptide is cleared (epigenetic)
  • Examples: Epitalon (AEDG), Pinealon (EDR), Vilon (KE)

All 11 Khavinson Bioregulators

Each bioregulator targets a specific organ system. This is organ-specific medicine at the peptide level — one compound, one target.

Epitalon
Target: Pineal Gland / Retina
AEDG
Telomerase activation (hTERT), melatonin circadian rhythm restoration, retinal integrity, gene expression regulation via histones H1/3 and H1/6. 44% telomere extension in normal cell lines (PMC12411320).
Oral
3–6 mg/day
Injectable
100–200 mcg/day
Pinealon
Target: Brain Cortex
EDR
Neuroprotection under hypoxic stress, memory enhancement (59.4% in TBI trial), NMDA excitotoxicity suppression, serotonin modulation, improved sleep architecture (REM + deep sleep).
Oral
1–2 mg/day
Injectable
200–500 mcg/day
Vesugen
Target: Blood Vessels
KED
Vascular integrity, endothelial cell support, microcirculation improvement. Targets blood vessel wall cells — relevant for cardiovascular health, capillary density, and blood pressure regulation.
Oral
20 mg/day
Injectable
2–3 mg/day
Vilon
Target: Thymus (Immune)
KE
Immune system restoration — specifically T-cell function. Dipeptide (just 2 amino acids). Studied for age-related immune decline (immunosenescence), autoimmune regulation, and thymic regeneration.
Oral
1–2 mg/day
Injectable
1–2 mg/day
Thymalin
Target: Thymus (Immune)
Polypeptide
The original thymic polypeptide complex (not a single short sequence). Extracted from calf thymus. Broader immune restoration than Vilon — the predecessor that validated the concept before synthetic versions were developed.
Oral
20–30 mg/day
Injectable
5–15 mg/day
Cortagen
Target: Brain Cortex
AEDP
Brain cortex bioregulator — more specific neurological targeting than Pinealon. Four amino acids vs Pinealon's three. Used for neurological conditions, cognitive decline, and brain aging. Shares the AED motif with Epitalon.
Oral
20 mg/day
Injectable
2–5 mg/day
Crystagen
Target: Immune System
EDP
Immunocompetent cell support — targets the broader immune system, not just thymus. Studied for immune enhancement in aging, post-infection recovery, and immune dysfunction. Tripeptide with glutamic acid-aspartic acid-proline sequence.
Oral
20 mg/day
Injectable
2–5 mg/day
Ovagen
Target: Liver / GI Tract
PGP
Hepatoprotective and GI tract support. Targets liver cells and gastrointestinal epithelium. Studied for liver cell regeneration, gut integrity, and protection against hepatic damage in animal models.
Oral
20 mg/day
Injectable
2–5 mg/day
Cartalax
Target: Cartilage / MSK
AED
Musculoskeletal system — targets cartilage cells (chondrocytes). Studied for joint health, cartilage regeneration, and protection against age-related musculoskeletal decline. Shares the AED core with Epitalon (AEDG).
Oral
20 mg/day
Injectable
2–5 mg/day
Chonluten
Target: Lungs / Bronchial
EDG
Pulmonary system support — targets bronchial and lung tissue cells. Studied for respiratory epithelium protection, pulmonary aging, and inflammation in lung tissue. EDG sequence shares the ED core with Pinealon.
Oral
20 mg/day
Injectable
2–5 mg/day
Testagen
Target: Testes / Reproductive
KEDG
Testicular bioregulator — targets Leydig and Sertoli cells. Studied for testosterone production support, spermatogenesis, and male reproductive aging. Four amino acids: lysine-glutamic acid-aspartic acid-glycine.
Oral
20 mg/day
Injectable
2–5 mg/day

Stacking Guide

Khavinson's research program used multiple bioregulators simultaneously. Here are the most studied and rationally designed combinations. Note: No human RCT data exists for most of these stacks specifically.

🌙 Sleep + Cognition
Epitalon (AEDG) Pinealon (EDR)
The most common bioregulator pair. Epitalon handles the when (pineal restoration, melatonin circadian rhythm). Pinealon handles the how well you recover (neuroprotection, memory consolidation, NMDA suppression). Complementary targets, synergistic effects.
⏳ Longevity Protocol
Epitalon (AEDG) Vilon (KE) Vesugen (KED)
Three-system longevity stack: pineal/telomere (Epitalon) + immune system restoration (Vilon) + vascular integrity (Vesugen). Based on Khavinson's model that aging proceeds via three parallel tracks: cellular, immune, and vascular decline.
🧠 Cognitive Performance
Pinealon (EDR) Vesugen (KED) Cortagen (AEDP)
Brain-focused stack: Pinealon for memory and neuroprotection, Vesugen for cerebral microcirculation (blood delivery to brain), Cortagen for broader neurological cell support. Rationale: cognition requires both healthy neurons and adequate blood supply.
🔄 Full System Reset (Khavinson Protocol)
Epitalon (AEDG) Pinealon (EDR) Vilon (KE) Vesugen (KED)
The comprehensive Khavinson protocol — four systems simultaneously: pineal/telomere, brain, immune, and vascular. Used in Russian longevity clinics for aging patients. Most aggressive in terms of peptide load. Not for beginners.

Cycling Protocol

Unlike traditional peptides with daily continuous use, bioregulators are typically cycled — matching how Khavinson's research program was structured.

🚀
Active Phase
10–30 days
Daily dosing. Initial phase or each cycle. Some protocols use 10 days, others go 20–30 days depending on the indication.
⏸️
Off Phase
2–3 months
Rest period between cycles. The epigenetic nature of bioregulators means effects may continue after the peptide clears.
🔁
Annual Cycles
1–3×/year
Most protocols run 1–3 cycles per year. More frequent cycling may be appropriate for individuals over 40 or with specific health goals.
Under 35
1–2 cycles per year typically sufficient. Systems are still relatively robust. Focus on Epitalon + Pinealon (sleep + cognition) rather than full protocol.
Over 40
More frequent cycling may be beneficial as natural bioregulator production declines. 2–3 cycles per year, broader stack (add Vilon + Vesugen for immune and vascular systems).

Oral Bioavailability of Ultra-Short Peptides

Most peptides are destroyed by stomach acid and gut enzymes. Bioregulators survive — and this is why.

🔬 The Science of Why They Survive

Traditional peptides (15–40+ amino acids) are large enough that proteases cleave them into individual amino acids before absorption. The biological signal is destroyed in transit.

Khavinson bioregulators are ultra-short (2–4 amino acids) — small enough to be transported intact across the intestinal epithelium by dedicated peptide transporters (PEPT1 and PEPT2). These transporters evolved to absorb short nutritional peptides — bioregulators exploit the same system.

This is why oral doses are higher than injectable doses (lower bioavailability is compensated with higher dose) but the oral route is still effective. The 72-patient TBI trial used oral Pinealon — demonstrating clinically meaningful effects via this route.

1
Survives Acid
Small size resists gastric acid degradation — the peptide bond in a 2–4 AA sequence is more stable than in longer chains
2
PEPT1/PEPT2 Transport
Dedicated intestinal di/tripeptide transporters carry them across the gut wall intact — the biological signal is preserved
3
Nuclear Entry
Once in circulation, the ultra-short size allows passage through cell membranes and into the nucleus where they interact with DNA

🛒 Recommended Supplies

Essential supplies for peptide research. For injectable protocols, these are the basics.

Affiliate links help support MeetPeptide at no extra cost to you.

Who Researches Bioregulators?

This Research Is Commonly Explored By People Who...

  • Are interested in Khavinson peptide bioregulators and their proposed gene expression regulation mechanisms
  • Want to understand the Russian clinical research on short peptides (2-4 amino acids) for organ-specific effects
  • Are exploring longevity and anti-aging research beyond mainstream Western approaches
  • Want to learn about epithalamin, vilon, cortagen, and other organ-specific bioregulators
  • Are curious about the intersection of peptide therapy and epigenetic regulation

This Research May Not Be Relevant If...

  • You expect Western-standard randomized controlled trials — most bioregulator data comes from Russian military and clinical research
  • You're looking for acute symptom treatment — bioregulators are studied as long-term, course-based interventions
  • You want widely available, pharmacy-dispensed medications — most bioregulators are specialty peptide products
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚕️ Disclaimer: This is educational content, not medical advice. Always consult a healthcare provider before making decisions about your health.
⚠️ Important Disclaimer

This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use any bioregulator peptide. None of the Khavinson bioregulators cataloged on this page are approved by the FDA or EMA for human use. They are research compounds. Russian clinical data, while extensive (15M patients, 40+ years, 6 approved Russian pharmaceuticals), has not been submitted for Western regulatory review under current RCT standards. Dosing information is derived from published research — not medical prescription. Always consult a qualified healthcare provider before making any health decisions. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.